Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Chief Business Officer | July 15, 2019 | July 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date July 15, 2019 · Filed July 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,573 |
Ending reported balance
After 2019-07-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-15 · Exercise / conversion · Acquired 3,542 · Balance 3,798 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit ("RSU") awards. Row 2 · 2019-07-15 · Tax withholding · Disposed 1,225 · Balance 2,573 F2: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,625 |
Reported balance
After 2019-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-15 · Exercise / conversion · Disposed 3,542 · Balance 10,625 F3: Each RSU represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: RSUs vest in four equal annual installments. Upon vesting, the RSUs will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit ("RSU") awards.
F2: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3: Each RSU represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4: RSUs vest in four equal annual installments. Upon vesting, the RSUs will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
1 source rowRow 1 · 2020-10-12 · Other · Disposed 242,978 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-12 · Disposition to issuer · Disposed 120,000 · Balance 0 F1: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $646,800.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-12 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,078,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $646,800.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F2: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,078,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2020 Filed Oct 13, 2020 15:54 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 200,000 | $5.39 Strike: $12.76 | $1,078,000.00 |
DisclosureSEC source: 0001209191-20-054613 · doc4.xml · derivative · entry 3 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-03-18 F2 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,078,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:54 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 120,000 | $5.39 Strike: $12.76 | $646,800.00 |
DisclosureSEC source: 0001209191-20-054613 · doc4.xml · derivative · entry 2 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2030-03-18 F1 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $646,800.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:54 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | OtherCommon Stock | 242,978 | $18.15 | $4,410,050.70 |
DisclosureSEC source: 0001209191-20-054613 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 16:19 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 8,709 | $18.12 | $157,807.08 |
DisclosureSEC source: 0001209191-20-051888 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,978 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on September 19, 2019. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:20 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 1,104 | $14.40 | $15,896.50 |
DisclosureSEC source: 0001209191-20-049120 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,687 F1 · kind: Although not required, the Reporting Person is voluntarily reporting the acquisition of 1,104 shares on August 31, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 16:41 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 9,417 | $11.75 | $110,648.81 |
DisclosureSEC source: 0001209191-20-021118 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,783 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on September 19, 2019. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:22 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-20-020632 · doc4.xml · derivative · entry 3 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-18 F2 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020; 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:22 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 109,800 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-20-020632 · doc4.xml · derivative · entry 2 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,800 Underlying: Common Stock · 109,800 shares Expires 2030-03-18 F2 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020; 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:22 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 55,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020632 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,200 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| March 19, 2020 Filed Mar 31, 2020 20:41 UTC Amendment | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-20-021951 · doc4a.xml · derivative · entry 2 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-03-18 F3 · shares: Due to a typographical error, the number of shares was incorrectly reported on the original Form 4 as 109,800 shares. F4 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020;1/48th of the shares vest monthly thereafter over the next three years. F3 · derivative.underlying_shares: Due to a typographical error, the number of shares was incorrectly reported on the original Form 4 as 109,800 shares. F3 · balance_after: Due to a typographical error, the number of shares was incorrectly reported on the original Form 4 as 109,800 shares. Read SEC document |
| March 19, 2020 Filed Mar 31, 2020 20:41 UTC Amendment | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021951 · doc4a.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 F1 · shares: Due to a typographical error, the number of shares was incorrectly reported on the original Form 4 as 55,200 shares. F2 · shares: Represents restricted stock unit award granted under the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 17:22 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $22.46 | $0.00 |
DisclosureSEC source: 0001209191-19-050481 · doc4.xml · derivative · entry 2 McDevitt Damien · CIK 0001742277 · Director · Interim Chief Executive Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-09-18 F1 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after September 19, 2019; 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 17:22 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050481 · doc4.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Director · Interim Chief Executive Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 3,542 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000114 · edgar.xml · derivative · entry 3 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 3,542 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: RSUs vest in four equal annual installments. Upon vesting, the RSUs will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: RSUs vest in four equal annual installments. Upon vesting, the RSUs will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 1,225 | $67.86 | $83,128.50 |
DisclosureSEC source: 0000874015-19-000114 · edgar.xml · nonDerivative · entry 2 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,573 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,542 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000114 · edgar.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit ("RSU") awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit ("RSU") awards. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 00:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 256 | $45.70 | $11,700.35 |
DisclosureSEC source: 0000874015-19-000081 · edgar.xml · nonDerivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256 F1 · kind: Reporting 256 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 256 shares may not be sold until January 2, 2020. F1 · shares: Reporting 256 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 256 shares may not be sold until January 2, 2020. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 13,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000018 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,065 Underlying: Common Stock · 13,065 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:46 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 29,400 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000012 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2026-01-01 F1 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| July 15, 2018 Filed Jul 16, 2018 22:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 14,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000099 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 14,167 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| June 18, 2018 Filed Jun 18, 2018 22:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 63,750 | $0.00 Strike: $43.60 | $0.00 |
DisclosureSEC source: 0000874015-18-000071 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2025-06-17 F1 · derivative.exercise_date: Grant of 6/18/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 6/18/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 6/18/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.